May 20, 2011 – Medrad Inc., a business of Bayer HealthCare, has announced the launch of the next generation Intego PET Infusion System, which features a new design that is 38% smaller, power-driven and includes enhancements to technologist workflow. The new Intego will be on display at the Annual Meeting of the Society of Nuclear Medicine (SNM), June 4-8, in San Antonio, Texas.
The Intego PET Infusion System, originally launched in 2008, remains the only FDA-cleared device for automated, controlled infusion of F18-FDG and F18-NaF, the most common PET diagnostic imaging agents used in oncology. Intego PET Infusion Systems have been sold throughout the world, including the United States, Latin America, South America, Europe, Africa, the Middle East, Asia and Australia.
For more information: www.medrad.com
July 30, 2024 
